Pharmaceutical

Health Canada list identifies select companies that can supply psilocybin to approved applicants through the Special Access Program for patient treatment

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its research facility, Numinus Bioscience, has been included on Health Canada's list of federally licensed psilocybin producers.

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with severe or life-threatening illness. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials.

"Through our inclusion, we look forward to collaborating with healthcare providers and other groups to ensure people in need receive efficacious treatments," said Sharan Sidhu , Science Officer and General Manager, Numinus Bioscience.

At this time, Numinus Bioscience is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15 and 25mg of psilocybin. These doses are produced under Good Agricultural and Collection Practices and tested for potency and impurities to support patient safety and practitioner confidence. With sufficient clinical data, Numinus may also make available other products that are currently being developed in its IP pipeline, should those meet the standards identified by Health Canada. With its Dealer's License and research facility, Numinus Bioscience is permitted to conduct several activities in addition to the production of psilocybin, including assembly, sale, export, analytical testing and R&D of ketamine, LSD and MDMA.

"Numinus is glad to see Health Canada committing to broadened mental healthcare access, starting with those in most need," said Payton Nyquvest , CEO and Founder, Numinus. "As clinical evidence grows, we look forward to making more treatments available and further advancing the development of psychedelic therapies and mental health innovations."

About Numinus
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at numinus.com and follow us on LinkedIn , Facebook , Twitter , and Instagram .

Forward-Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

Cision View original content: https://www.prnewswire.com/news-releases/numinus-identified-as-a-licensed-psilocybin-supplier-by-health-canada-301469357.html

SOURCE Numinus Wellness Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/January2022/27/c5591.html

News Provided by Canada Newswire via QuoteMedia

NUMI:CA

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services,
accelerates IP development and increases psychedelic supply capacity

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021.

Keep reading... Show less

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the Company's ability to lead psychedelics research and support the global psychedelics sector.

Keep reading... Show less

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

Keep reading... Show less

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research
capabilities ensure Numinus' continued growth

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 ("Q1 2021"). After achieving two industry firsts, launching new compassionate access trials, and augmenting its clinical and research activity, Numinus meaningfully expanded its industry presence in Q1 2021. All financial results are reported in Canadian dollars unless otherwise stated.

Keep reading... Show less
wine tasting at table

Are Tobacco and Alcohol Firms Still Interested in Cannabis?

An analyst with experience overseeing tobacco and alcohol players believes there’s no doubt these companies want a piece of the cannabis pie, but told the Investing News Network (INN) that they are unsure of the best approach after previous blunders.

Shane MacGuill is the global lead of nicotine and cannabis with Euromonitor International, a strategic market research company evaluating the European territory, a burgeoning arena for cannabis.

The expert explained that his client base looks to the firm for periodically updated data-based reports. Some of those clients include consumer packaged goods (CPG) and fast-moving consumer goods companies.

Keep reading... Show less

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Curaleaf began serving New Jersey adult-use customers at its Bellmawr location in April

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, will begin adult-use sales at its Edgewater Park, New Jersey dispensary on May 25 . Located at 4237 US-130, Curaleaf Edgewater Park is now the Company's second location to sell adult-use cannabis in the Garden State.

Keep reading... Show less

Curaleaf Appoints Tyneeha Rivers As Chief People Officer

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf'' or the "Company"), a leading international provider of consumer products in cannabis, announced today that Tyneeha Rivers has been appointed to the role of Chief People Officer for Curaleaf, a new position.

The move follows the recent announcement of Matt Darin being named CEO, replacing Joe Bayern , who will be launching a new CPG focused division of the Company.

Keep reading... Show less
Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of Aureus Branded THC and CBD Extracts to Portugal

Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of Aureus Branded THC and CBD Extracts to Portugal

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (" SMGH "), SMGH has completed its first commercial export of high concentration THC and high concentration CBD full spectrum psychoactive cannabis extracts to Portugal.

Keep reading... Show less
AgriForce to Present at the H.C. Wainwright Global Investment Conference on May 25th

AgriForce to Present at the H.C. Wainwright Global Investment Conference on May 25th

AGRIFORCE Growing Systems Ltd. ("the Company") (NASDAQ: AGRI; AGRIW) an intellectual property (IP)-focused AgTech company dedicated to advancing sustainable cultivation and crop processing across multiple verticals, today announced that Ingo Mueller, Chief Executive Officer of AGRIForce, will be presenting at the H.C. Wainwright Global Investment Conference which is being held on May 23- May 26, 2022 at the Fontainebleau Miami Beach Hotel, Miami FL. The conference will include virtual and in-person participation.

Mr. Mueller is scheduled to present in-person on Wednesday, May 25, 2022 at 12:00 p.m. ET. Management will also be available for one-on-one meetings with qualified investors throughout the conference.

Keep reading... Show less
person working on laptop

Cannabis Weekly Round-Up: Cresco and Columbia Care Share Q1 Financials

A pair of US cannabis companies that are tied together by an acquisition plan released their quarterly financials this week. Cannabis delivery services were in focus as well as two companies confirmed their plans to offer seamless delivery solutions for cannabis consumers.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less

Latest Press Releases

Related News

×